Liver TransplantationPLVT_THNCT07582978
Impact of the Procurement Technique on Outcomes After Liver Transplantation
An observational study of Liver Transplantation, run by Assistance Publique - Hôpitaux de Paris.
Trial summary
Liver transplantation (LT) is the standard treatment for hepatocellular carcinoma (HCC) and end-stage liver disease, with excellent long-term outcomes despite the increasing use of extended criteria donors due to organ shortage. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Liver Transplantation
- How many people
- 1,810 participants
- Where
- No sites listed yet
- Study dates
- Sep 2026to Sep 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: adult patients (≥18 years) who undergo a first liver transplantation in France.
Who may be able to join
- Patients aged 18 years or older at the time of inclusion
- Listed on the national waiting list of the Agence de la Biomédecine (ABM)
- Undergoing a first liver transplantation in France
- Receiving a whole liver graft
- No prior or subsequent transplantation of another organ
Who cannot join
- Pancreas procurement
- Multiorgan transplantation
- Split liver transplantation (shared grafts)
- Retransplantation
- Domino transplantation (no actual organ procurement in the conventional sense)
- Patient refusal to allow the use of their data
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Jinmi BAEK contact
About this study
Official title: Impact of the Procurement Technique on Outcomes After Liver Transplantation: a French Multicenter Prospective Study
Liver transplantation (LT) is the standard treatment for hepatocellular carcinoma (HCC) and end-stage liver disease, with excellent long-term outcomes despite the increasing use of extended criteria donors due to organ shortage. As traditional evaluation criteria have become insufficient, new indicators such as Arterial and Biliary Complication-Free Survival (ABCFS) have been developed to better assess post-transplant outcomes.
Primary objective: To assess, in a large-scale study, whether the procurement technique influences liver transplantation outcomes in terms of arterial and biliary complication-free survival.
- Conditions
- Liver Transplantation
- Keywords
- liver transplantation, LT, hepatocellular carcinoma (HCC), Arterial and Biliary Complication-Free Survival, procurement technique
- Medical subject headings
- Carcinoma, Hepatocellular
What is being measured
The primary outcome is the main question the study is designed to answer.
Arterial and Biliary Complication-Free Survival (ABCFS) at 3 years
Measured: at 3 years post-transplantation
Secondary outcomes (7)
Postoperative complications at 90 days
Measured: at 90 days post-transplantation
Type of Biliary complications
Measured: Up to 3 years post-transplantation
Type of Arterial complications
Measured: Up to 3 years post-transplantation
Occurrence of vascular injuries observed following organ procurement
Measured: Peri-procedural period (during procurement and immediately post-procurement)
Rehospitalization Rate Post-LT
Number of rehospitalizations per patient occurring after the initial transplantation hospitalization.
Measured: Up to 3 years post-transplantation
Duration of Rehospitalizations Post-LT
Length of stay for each rehospitalization occurring after the initial transplantation hospitalization.
Measured: Up to 3 years post-transplantation
Reasons for Rehospitalizations Post-LT
Reason for each rehospitalization occurring after the initial transplantation hospitalization, categorized by diagnosis.
Measured: Up to 3 years post-transplantation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2026
- Study startSep 2026 (estimated)
- Primary completionSep 2031 (estimated)
- Study completionSep 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver TransplantationStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,810 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Astrid HERRERO, MD, PhD, Study chair, Saint Eloi Hospital, Montpellier University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07582978
- Sponsor's protocol ID
- APHP250871
- Acronym
- PLVT_TH
- Status last verified
- May 2026
- First submitted
- 28 Apr 2026
- Last updated
- 13 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of the Procurement Technique on Outcomes After Liver Transplantation: a French Multicenter Prospective Study
- ClinicalTrials.gov ID
- NCT07582978
- Acronym / sponsor ID
- PLVT_TH / APHP250871
- Conditions
- Liver Transplantation
- Keywords
- liver transplantation, LT, hepatocellular carcinoma (HCC), Arterial and Biliary Complication-Free Survival, procurement technique
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,810 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- Sep 2026 (estimated)
- Primary completion
- Sep 2031 (estimated)
- Study completion
- Sep 2031 (estimated)
- First posted
- 13 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Liver transplantation (LT) is the standard treatment for hepatocellular carcinoma (HCC) and end-stage liver disease, with excellent long-term outcomes despite the increasing use of extended criteria donors due to organ shortage. As traditional evaluation criteria have become insufficient, new indicators such as Arterial and Biliary Complication-Free Survival (ABCFS) have been developed to better assess post-transplant outcomes.
Primary objective: To assess, in a large-scale study, whether the procurement technique influences liver transplantation outcomes in terms of arterial and biliary complication-free survival.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- adult patients (≥18 years) who undergo a first liver transplantation in France.
Key inclusion criteria (5 listed)
- Patients aged 18 years or older at the time of inclusion
- Listed on the national waiting list of the Agence de la Biomédecine (ABM)
- Undergoing a first liver transplantation in France
- Receiving a whole liver graft
- No prior or subsequent transplantation of another organ
Key exclusion criteria (6 listed)
- Pancreas procurement
- Multiorgan transplantation
- Split liver transplantation (shared grafts)
- Retransplantation
- Domino transplantation (no actual organ procurement in the conventional sense)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Arterial and Biliary Complication-Free Survival (ABCFS) at 3 years
Time frame: at 3 years post-transplantation
7 secondary outcomes
Postoperative complications at 90 days
Time frame: at 90 days post-transplantation
Type of Biliary complications
Time frame: Up to 3 years post-transplantation
Type of Arterial complications
Time frame: Up to 3 years post-transplantation
Occurrence of vascular injuries observed following organ procurement
Time frame: Peri-procedural period (during procurement and immediately post-procurement)
Rehospitalization Rate Post-LT
Time frame: Up to 3 years post-transplantation
Duration of Rehospitalizations Post-LT
Time frame: Up to 3 years post-transplantation
Reasons for Rehospitalizations Post-LT
Time frame: Up to 3 years post-transplantation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.
- Individual participant dataSharing planned: No
Related trials for Liver Transplantation
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
RecruitingPhase 2
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Liver Transplant
RecruitingObservational study
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jinmi BAEK contact
Astrid HERRERO, MD, PhD study chair
Saint Eloi Hospital, Montpellier University Hospital
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Transplantation, run by Assistance Publique - Hôpitaux de Paris.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eric Savier, MD, PhD (+33 1 42 17 56 90, eric.savier@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Arterial and Biliary Complication-Free Survival (ABCFS) at 3 years (time frame: at 3 years post-transplantation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.